Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.__)

Filed by the Registrantx

Filed by a Party other than the Registranto

Check the appropriate box:


Preliminary Proxy Statement


Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))


Definitive Proxy Statement


Definitive Additional Materials


Soliciting Material Pursuant to § 240.14a-12

Atara Biotherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):


No fee required.


Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.


Title of each class of securities to which transaction applies:



Aggregate number of securities to which transaction applies:



Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):



Proposed maximum aggregate value of transaction:



Total fee paid:



Fee paid previously with preliminary materials.


Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid:



Form, Schedule or Registration Statement No.:



Filing Party:



Date Filed:








0000248491_1  R1.0.0.51160   ATARA BIOTHERAPEUTICS, INC.     ATARA BIOTHERAPEUTICS, INC.  3260 BAYSHORE BOULEVARD  BRISBNE, CA 94005   Investor Address Line 1  Investor Address Line 2  Investor Address Line 3  Investor Address Line 4  Investor Address Line 5  John Sample  1234 ANYWHERE STREET  ANY CITY, ON A1A 1A1    June 25, 2015   Annual Meeting  April 27, 2015   June 25, 2015 9:00 AM PDT  701 Gateway Blvd.  Suite 200   S. San Francisco, CA 94080



1. Notice & Proxy Statement 2. Annual Report  Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment  advisor. Please make the request as instructed above on or before June 11, 2015 to facilitate timely delivery.   0000248491_2  R1.0.0.51160



The Board of Directors recommends you vote  FOR the following:   1.  Election of Directors  Nominees  01  Eric L. Dobmeier 02 Beth Seidenberg, M.D. 03 Eckard Weber, M.D.   The Board of Directors recommends you vote FOR the following proposal:   2  Ratification of the appointment of Deloitte & Touche, LLP as the Company's independent auditors for the year  ending December 31, 2015.   NOTE: In their discretion, upon such other matters that may properly come before the meeting or any adjournment or  adjournments thereof.   0000248491_3  R1.0.0.51160  



0000248491_4  R1.0.0.51160 NAME THE COMPANY NAME INC. - COMMON 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS A 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS B 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS C 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS D 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS E 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS F 123,456,789,012.12345 THE COMPANY NAME INC. - 401 K 123,456,789,012.12345 THIS SPACE RESERVED FOR SIGNATURES IF APPLICABLE Reserved for Broadridge Internal Control Information Broadridge Internal Use Only Job # Envelope # Sequence # # of # Sequence #